1 in 5 reprocessed SUDs (single-use devices) pulled for failing validation
This article was originally published in Clinica
Companies reprocessing single-use devices (SUDs) in the US are having trouble complying with the FDA's new requirement that validation data be provided for certain potentially risky products already on the market, agency officials have told Clinica.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.